Literature DB >> 27865461

Molecular and Cellular Changes During Cancer Progression Resulting From Genetic and Epigenetic Alterations.

K Pruitt1.   

Abstract

Tumorigenesis is a complex process that involves a persistent dismantling of cellular safeguards and checkpoints. These molecular and cellular changes that accumulate over months or decades lead to a change in the fundamental identity of a cell as it transitions from normal to malignant. In this chapter, we will examine some of the molecular changes in the evolving relationship between the genome and epigenome and highlight some of the key changes that occur as normal cells progress to tumor cells. For many years tumorigenesis was almost exclusively attributed to mutations in protein-coding genes. This notion that mutations in protein-coding genes were a fundamental driver of tumorigenesis enabled the development of several novel therapeutics that targeted the mutant protein or overactive pathway responsible for driving a significant portion of the tumor growth. However, because many therapeutic challenges remained in the face of these advances, it was clear that other pieces to the puzzle had yet to be discovered. Advances in molecular and genomics techniques continued and the study of epigenetics began to expand and helped reshape the view that drivers of tumorigenesis extended beyond mutations in protein-coding genes. Studies in the field of epigenetics began to identify aberrant epigenetic marks which created altered chromatin structures and enabled protein expression in tissues that defied rules governing tissue-specificity. Not only were epigenetic alterations found to enable overexpression of proto-oncogenes, they also led to the silencing of tumor suppressor genes. With these discoveries, it became clear that tumor growth could be stimulated by much more than mutations in protein-coding genes. In fact, it became increasingly clear that much of the human genome, while transcribed, did not lead to proteins. This discovery further led to studies that began to uncover the role of noncoding RNAs in regulating chromatin structure, gene transcription, and tumor biology. In this chapter, some of the key alterations in the genome and epigenome will be explored, and some of the cancer therapies that were developed as a result of these discoveries will be discussed.
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acetylation; Cancer epigenetics; Cancer genetics; Chromatin; Epigenome; Histone; Methylation

Mesh:

Substances:

Year:  2016        PMID: 27865461     DOI: 10.1016/bs.pmbts.2016.09.001

Source DB:  PubMed          Journal:  Prog Mol Biol Transl Sci        ISSN: 1877-1173            Impact factor:   3.622


  10 in total

Review 1.  Chromatin-Remodeled State in Lymphoma.

Authors:  Yuxuan Liu; Yulissa Gonzalez; Jennifer E Amengual
Journal:  Curr Hematol Malig Rep       Date:  2019-10       Impact factor: 3.952

Review 2.  Hormonal and Genetic Regulatory Events in Breast Cancer and Its Therapeutics: Importance of the Steroidogenic Acute Regulatory Protein.

Authors:  Pulak R Manna; Ahsen U Ahmed; Deborah Molehin; Madhusudhanan Narasimhan; Kevin Pruitt; P Hemachandra Reddy
Journal:  Biomedicines       Date:  2022-06-03

3.  Overexpression of the steroidogenic acute regulatory protein in breast cancer: Regulation by histone deacetylase inhibition.

Authors:  Pulak R Manna; Ahsen U Ahmed; David Vartak; Deborah Molehin; Kevin Pruitt
Journal:  Biochem Biophys Res Commun       Date:  2018-12-27       Impact factor: 3.575

4.  Nuclear Dishevelled targets gene regulatory regions and promotes tumor growth.

Authors:  Isabel Castro-Piedras; Monica Sharma; Jennifer Brelsfoard; David Vartak; Edgar G Martinez; Cristian Rivera; Deborah Molehin; Robert K Bright; Mohamed Fokar; Josee Guindon; Kevin Pruitt
Journal:  EMBO Rep       Date:  2021-04-16       Impact factor: 9.071

5.  DVL1 and DVL3 differentially localize to CYP19A1 promoters and regulate aromatase mRNA in breast cancer cells.

Authors:  Isabel Castro-Piedras; Monica Sharma; Meghan den Bakker; Deborah Molehin; Edgar G Martinez; David Vartak; Wendy M Pruitt; Jena Deitrick; Sharilyn Almodovar; Kevin Pruitt
Journal:  Oncotarget       Date:  2018-11-02

6.  Acetylation of conserved DVL-1 lysines regulates its nuclear translocation and binding to gene promoters in triple-negative breast cancer.

Authors:  Monica Sharma; Deborah Molehin; Isabel Castro-Piedras; Edgar G Martinez; Kevin Pruitt
Journal:  Sci Rep       Date:  2019-11-07       Impact factor: 4.379

7.  Epigenetic Modifications in Peripheral Blood as Potential Noninvasive Biomarker of Diabetic Retinopathy.

Authors:  Arul J Duraisamy; Rakesh Radhakrishnan; Berhane Seyoum; Gary W Abrams; Renu A Kowluru
Journal:  Transl Vis Sci Technol       Date:  2019-12-18       Impact factor: 3.283

Review 8.  The Versatility of Sirtuin-1 in Endocrinology and Immunology.

Authors:  Fahmida Rasha; Brianyell McDaniel Mims; Isabel Castro-Piedras; Betsy J Barnes; Matthew B Grisham; Rakhshanda Layeequr Rahman; Kevin Pruitt
Journal:  Front Cell Dev Biol       Date:  2020-11-19

9.  Identification of Novel MeCP2 Cancer-Associated Target Genes and Post-Translational Modifications.

Authors:  Isabel Castro-Piedras; David Vartak; Monica Sharma; Somnath Pandey; Laura Casas; Deborah Molehin; Fahmida Rasha; Mohamed Fokar; Jacob Nichols; Sharilyn Almodovar; Rakhshanda Layeequr Rahman; Kevin Pruitt
Journal:  Front Oncol       Date:  2020-12-10       Impact factor: 6.244

10.  Diagnostic performance of SHOX2 promoter methylation as biomarker for lung cancer identification: A meta-analysis update.

Authors:  Xiaoxi Zhou; Xiaoling Lu; Haiyan Wu; Juan Liu; He Huang
Journal:  Thorac Cancer       Date:  2021-11-05       Impact factor: 3.500

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.